YOLFTbeta
30

Hubei Biocause Heilen Pharmaceutical Co. Ltd.

301211 · SHE · Healthcare / Drug Manufacturers - Specialty & Generic

10.66CNY-0.35 (-3.18%)

Price History

Full chart

Market Stats

Previous Close11.01
Open11.01
Day Range10.60 – 11.01
52-Week Range9.01 – 16.84
Volume6.65M
Market Cap5.30B
P/E (TTM)115.45
Forward P/E0.00
EPS0.11
Dividend Yield0.47%
Beta0.54
50-Day Avg11.78
200-Day Avg11.83

About

Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. It is involved in the research and development, production, and sales of chemical raw materials and preparations; and provision of contract research and development, and production services. The company also provides raw material products, including non-steroidal anti-inflammatory raw materials ibuprofen and dexibuprofen, cardiovascular raw materials torsemide and milrinone, anti-tumor raw materials abiraterone acetate, fludarabine phosphate, and granisetron hydrochloride; and preparation products, such as cardiovascular preparations torsemide tablets and non-steroidal anti-inflammatory preparations ibuprofen granules, and other preparations. In addition, it offers non-anti-inflammatory APIs, cardiovascular, anti-tumor, and anticholinergic APIs and intermediates; antipyretic and analgesic, cardiovascular and anti-infective preparations; and chemicals and formulations. Hubei Biocause Heilen Pharmaceutical Co., Ltd. was founded in 1995 and is based in Jingmen, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Qun Liang
  • Employees952
  • HeadquartersNo. 122 Yangwan Road, Jingmen, China, 448000, China
  • Websitehttps://www.biocause.com

Leadership

  • Mr. Qun LiangGeneral Manager · b. 1971
  • Mr. Ting Hao YiFinancial Director · b. 1973
  • Ms. Chunli YangExecutive VP & Director · b. 1970
  • Mr. Jian GaoBoard Secretary · b. 1977
  • Mr. Zhenghua HuangDeputy General Manager · b. 1972
  • Mr. Weihua ZhuDeputy General Manager · b. 1967
  • Ms. Kuili ZhangDeputy General Manager · b. 1976
  • Ms. Qianqian GuanDeputy General Manager · b. 1983
  • Chun Hua QuanAccounting Supervisor

Financials

Income Statement

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue366.41M517.14M660.02M592.92M540.62M514.91M663.03M445.86M453.31M
Growth (%)-+41.14%+27.63%-10.17%-8.82%-4.76%+28.76%-32.75%+1.67%
Cost of Revenue265.68M295.63M319.23M298.54M358.33M369.78M397.55M317.79M353.10M
Gross Profit100.73M221.52M340.79M294.38M182.30M145.13M265.47M128.07M100.20M
Gross Margin27.49%42.83%51.63%49.65%33.72%28.18%40.04%28.72%22.10%
Operating Expense73.78M114.07M122.69M95.42M43.01M-3.60M60.14M27.19M92.80M
Operating Income26.96M107.45M218.10M198.96M139.29M148.73M205.33M100.88M7.41M
Operating Margin7.36%20.78%33.04%33.56%25.76%28.88%30.97%22.63%1.63%
EBITDA45.46M129.61M243.02M219.33M158.92M168.16M223.62M125.00M84.81M
EBITDA Margin12.41%25.06%36.82%36.99%29.40%32.66%33.73%28.04%18.71%
Net Income10.27M47.74M100.29M168.07M121.65M125.79M176.12M91.55M34.91M
Net Income Margin2.80%9.23%15.19%28.35%22.50%24.43%26.56%20.53%7.70%
R&D17.70M20.87M24.99M22.98M18.28M19.84M52.77M32.94M25.18M
R&D as % of Total Revenue4.83%4.04%3.79%3.87%3.38%3.85%7.96%7.39%5.55%
Interest Expense2.77M6.94M4.27M2.51M372.56K344.41K576.27K534.45K179.05K
Interest Expense % of Total Revenue0.76%1.34%0.65%0.42%0.07%0.07%0.09%0.12%0.04%

Balance Sheet

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets534.90M640.24M745.56M803.25M2.33B2.50B2.55B2.49B2.40B
Total Liabilities227.25M240.36M257.31M102.85M107.53M221.22M189.89M178.97M128.65M
Total Equity237.61M286.09M488.25M700.39M2.22B2.28B2.36B2.31B2.27B
Cash48.82M61.63M71.06M105.27M1.86B1.86B1.69B543.14M447.66M
Total Debt102.00M117.00M20.00M7.26M30.26M7.40M5.15M19.24M-
Net Debt53.18M55.37M-51.06M-98.01M-1.83B-1.85B-1.69B-539.51M-

Cash Flow

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-65.44M76.18M372.33M121.67M123.98M250.79M137.06M96.07M7.55M
Investing Cash Flow-12.98M-68.87M-256.03M44.35M229.65M-179.86M-207.47M-1.11B-
Financing Cash Flow49.23M8.55M-108.83M-123.37M1.41B-77.39M-97.17M-139.87M-
Capital Expenditure13.12M25.08M32.34M13.39M21.07M75.95M186.53M164.43M52.33M
Free Cash Flow-78.56M51.11M339.98M108.28M102.92M174.84M-49.47M-68.36M-44.78M
Dividends Paid2.77M6.45M3.92M2.28M-72.00M96.00M138.24M72.00M
FCF to OCF120.05%67.08%91.31%89.00%83.01%69.72%-36.09%-71.15%-593.03%
Dividend Paid to FCF-3.53%12.62%1.15%2.11%-41.18%-194.06%-202.23%-160.79%

Earnings

Report DateDec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026
EPS Estimate------------------
EPS Actual0.050.070.060.060.110.100.180.080.080.090.070.010.040.020.020.010.030.02
Surprise------------------
Timing------------------

Key Statistics & Ratios

Market Cap5.30B
Enterprise Value3.72B
Trailing P/E115.45
Forward P/E0.00
Price / Sales11.38
Price / Book2.31
EPS0.11
Book Value5.46
Revenue (TTM)466.05M
Gross Profit (TTM)103.69M
EBITDA54.13M
Profit Margin9.98%
Operating Margin5.40%
Return on Equity2.05%
Return on Assets0.26%
Shares Outstanding417.60M
Shares Float167.32M
Beta0.54
Dividend Yield0.47%
Dividend Rate0.06
Payout Ratio97.88%

Dividends

20261×
0.06Jun 12, 2026
20251×
0.17May 26, 2025
20241×
0.33May 27, 2024
20231×
0.28May 31, 2023
20221×
0.17Jul 6, 2022

Stock Splits

  • Aug 27, 20251.45:1
  • May 31, 20231.2:1